Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 13/20 | 0.74 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.74 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.74 |
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.68 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.63 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.59 |
| ▸ | FADS1 | O60427 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330581 | 0.88 | P2RX1 (0.76) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL11932152 | 0.86 | P2RX1 (1.00) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL13812564 | 0.85 | TMPRSS4 (0.74) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL18341409 | 0.85 | P2RX1 (0.77) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL13812565 | 0.83 | P2RX1 (0.78) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL30771751 | 0.83 | P2RX1 (0.69) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL26980263 | 0.83 | P2RX1 (0.69) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL538439 | 0.81 | TMPRSS4 (1.00) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL3860231 | 0.81 | P2RX1 (0.78) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 | |
| SCHEMBL11932156 | 0.81 | P2RX1 (0.78) | P2RX1P2RX4P2RX7TMPRSS4SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | P2RX1 2484/4885P2RX4 3324/4885P2RX7 2360/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | P2RX1 2927/4885P2RX4 3704/4885P2RX7 2720/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | P2RX1 3156/4885P2RX4 4233/4885P2RX7 3197/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | P2RX1 2425/4885P2RX4 3298/4885P2RX7 2267/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | P2RX1 2389/4885P2RX4 3242/4885P2RX7 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.